Floatz logo

Blu-701

Lung Neoplasm

Blueprint Medicines CorporationPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

51 Active assets in the Lung Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
Nivolumab
Hospital Israelita Albert Einstein
Phase 2BB
BELAGENPUMATUCEL-L (SK-LU-1)
NovaRx Corporation
Phase 3BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Rivoceranib
Fuzhou General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Blu-701 is also rated in:

chemotherapy-induced toxicityDormant
CC
Indicative ·
43 / 100
View asset →
respiratory tract neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
respiratory system disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →